Pilot Study of Ursodesoxycholic Acid in Non-Alcoholic Steatohepatitis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

98 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-10-31

Study Completion Date

2008-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a phase II study with direct individual benefit. It is a randomized, double blind placebo controlled study whose aim is to evaluate the efficacy and tolerance of ursodesoxycholic acid in patients who have been diagnosed with non-alcoholic steatohepatitis.

The hepatoprotective effects of ursodesoxycholic acid may ameliorate the hepatic impairment associated with non-alcoholic steatohepatitis leading to subsequent significant decreases in transaminase elevations and non-invasive markers for hepatic fibrosis A positive response is defined as a significantly larger decrease in average ALAT levels between the time of inclusion in the study and the end of the treatment for the ursodesoxycholic acid group as compared to the placebo group.

The duration of the study will be 12 months. An end of treatment evaluation (EoT) will take place at the end of the 12th month of treatment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

FM101 Efficacy Study in Adults With Nonalcoholic Fatty Liver Disease or Nonalcoholic Steatohepatitis

NCT04710524

Nonalcoholic Fatty Liver Disease Nonalcoholic Steatohepatitis

UNKNOWN PHASE2

Norursodeoxycholic Acid vs. Placebo in NASH

NCT05083390

Nonalcoholic Steatohepatitis

RECRUITING PHASE2

Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment

NCT02548351

Non Alcoholic Steatohepatitis (NASH)

TERMINATED PHASE3

Ursodeoxycholic Acid in Patients With NAFLD - Clinical Observation

NCT05256979

Non-Alcoholic Fatty Liver Disease

ACTIVE_NOT_RECRUITING

A Pilot Study of Fenofibrate and Ursodeoxycholic Acid in the Treatment of Newly Diagnosed Primary Biliary Cholangitis

NCT06591455

Primary Biliary Cholangitis (PBC)

COMPLETED EARLY_PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Serum Levels of ALAT Transaminases Serum Markers for Fibrosis and Hepatic Inflammation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ursodesoxycholic acid

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Greater than 18 years of age.
* Hepatic biopsy consistent with non-alcoholic steatohepatitis: presence of \>20% steatosis associated with hepatocyte swelling and/or intralobular necrosis within the last 18 months.
* Serum levels of ALAT and/or ASAT \> 50 UI/L at the time of screening (with at least 3 elevated transaminase values within the last 12 months).

Exclusion Criteria

* Hepatic biopsy not performed within the last 18 months.
* A single normal transaminase value within the last 12 months.
* Treatment with ursodesoxycholic acid within the last 12 months.
* Loss of more than 15% body weight between the time of the liver biopsy and the time of screening.
* Alcohol consumption of \>20 g/day for women and \> 30 g/day for men
* Hepatitis from other causes: chronic viral hepatitis B or C, elevated ferritin levels associated with C282Y homozygosity, primary biliary cirrhosis, primary sclerosing cholangitis, well documented auto-immune hepatitis (specific autoantibodies, hypergammaglobulinemia, consistent histologic changes), alpha1 antitrypsin deficiency, Wilson's disease, HIV infection.
* NASH from secondary causes: long term amiodarone administration, corticosteroid therapy, anti-obesity surgery within the last 2 years, tamoxifen.
* Child's type B or C cirrhosis.
* Presence of hepatocellular carcinoma.
* Treatment with rosiglitazone or pioglitazone currently or during the 3 preceding years, treatment with Vitamin E within the 6 months prior to screening.
* Women who are pregnant or nursing.
* Unavailability of hepatic biopsy slides for centralized interpretation.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No